Project Sage Oldco Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Project Sage Oldco şirketinin toplam hissedar öz sermayesi $-32.0M ve toplam borcu $58.8M olup, bu da borç-öz sermaye oranını -183.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $139.9M ve $172.0M dir.

Anahtar bilgiler

-183.5%

Borç/özkaynak oranı

US$58.81m

Borç

Faiz karşılama oranı	n/a
Nakit	US$15.03m
Eşitlik	-US$32.04m
Toplam yükümlülükler	US$171.98m
Toplam varlıklar	US$139.93m

Son finansal sağlık güncellemeleri

Recent updates

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Jul 06

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Apr 16

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Jan 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SIEN.Q negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: SIEN.Q şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SIEN.Q negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: SIEN.Q 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SIEN.Q şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: SIEN.Q tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Project Sage Oldco Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Recent updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc.(OTCPK:SIEN.Q) dropped from NASDAQ Composite Index

DIP Financing Approved for Sientra, Inc.

Motion for Asset Sale Filed by Sientra, Inc.

Sientra, Inc. Filed for Bankruptcy

Sientra, Inc. Filed for Bankruptcy

Sientra Receives Non-Compliance Notice from Nasdaq

Consensus EPS estimates fall by 15%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sientra, Inc. Appoints Alexander W. Casdin to the Company’s Board of Directors, Effective June 15, 2023

Sientra Announces FDA-Clearance of Next Generation Allox2 Pro Tissue Expander

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Full year 2022 earnings: EPS misses analyst expectations

Sientra, Inc. Announces Launch of Viality, Novel Fat Transfer System

Insider recently bought US$933k worth of stock

Price target decreased to US$2.08

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sientra, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sientra, Inc. has completed a Follow-on Equity Offering in the amount of $29.217384 million.

Sientra slides 18% on proposes stock offering

Sientra, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra Receives Written Notice from the Listing Qualifications Department of Nasdaq

Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Sientra, Inc. Revises Revenue Guidance for the Year 2022

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra, Inc. to Report Q2, 2022 Results on Aug 11, 2022

FDA Approves Sientra’s Low Plus Profile Projection Breast Implant

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra, Inc.(NasdaqGS:SIEN) dropped from Russell 2000 Dynamic Index

Price target decreased to US$6.33

Sientra, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.83

Sientra, Inc. to Report Q1, 2022 Results on May 12, 2022

Sientra, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$7.67

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Consensus EPS estimates fall by 31%

Price target decreased to US$10.60

Sientra, Inc. Provides Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.097 loss per share (vs US$0.12 loss in 3Q 2020)

Lead Independent Director Nicholas Simon has left the company

Sientra, Inc. Increases Earnings Guidance for the Full Year 2021

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.68 loss in 2Q 2020)

1315 Capital, LLC completed the acquisition of miraDry business of Sientra, Inc. (NasdaqGS:SIEN).

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin